Protocol for Dex-CSDH published by BMC
A corrected protocol for a trial of dexamethasone for adult patients with a symptomatic chronic subdural haematoma (Dex-CSDH) has recently been published in a BioMed Central Journal.
Professor of Neurosurgery, University of Cambridge
Dex-CSDH, led by Peter Hutchinson (Medicine) and sponsored by CUHFT/ University of Cambridge, is a pragmatic, multi-centre, double-blind, phase III randomised, placebo-controlled trial (n=750) assessing the clinical utility of a tapering 2-week course of dexamethasone following Chronic Subdural Haematoma. Stage 1 will take place initially in a limited number of centres in the UK, to ensure feasibility. If successful, stage 2 will follow and will encompass, where possible, all remaining Neurosurgical centres in the UK and the Republic of Ireland.
Stage 1 aims to recruit 100 patients within 12 months. If the progression rules are met, Stage 2 will recruit 650 patients within 2 years. The recruitment rate has been estimated at 2 patients per site per month. On the basis of hospital episode statistics (HES) and data from the ongoing national CSDH audit, approximately 60-80 patients with a CSDH are admitted in a medium-sized neurosurgical unit each year. Hence, the estimated recruitment rate is feasible. Patients will be monitored whilst in the acute Neurosurgical unit and followed up for a period of 6 months post recruitment.
For more information visit: BioMed Central
Published January 6, 2020
Latest from CCTU
New clues about irritable bowel syndrome found in the brain
Breakthrough research led by Addenbrooke's Hospital gives IBS patients like Laura Tebbs a better understanding of their condition.
Researchers eye up new gene therapy trial that could reverse hereditary blindness
Restoration of sight from a rare genetic mutation may now become a reality thanks to a prestigious award from the National Institute for Health Research (…
Artificial pancreas trialled for outpatients with type 2 diabetes for first time
An artificial pancreas could soon help people living with type 2 diabetes and who also require kidney dialysis.
